Correction to “Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell‐Related Autoimmune Diseases”

Documenti analoghi

• Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response
  di: Andrea Fava, et al.
  Pubblicazione: (2024)
• Correction to CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus
  Pubblicazione: (2025)
• Mechanisms of B Cell Tolerance in Health and Autoimmunity
  di: Sivasankaran Munusamy Ponnan, et al.
  Pubblicazione: (2025)
• Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus
  di: Hugo J. van Dooren, et al.
  Pubblicazione: (2025)
• Precision Medicine in Pediatric Autoimmunity: Leniolisib Treatment of Childhood‐Onset Lupus Nephritis Due to Activated Phosphoinositide 3‐Kinase δ Syndrome
  di: Jonathan P. Lim, et al.
  Pubblicazione: (2025)